PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Phase 1

Terminated

• Conditions: Gynecologic Neoplasms; Epithelial Ovarian Cancer
• Interventions: Drug: PLX2853; Drug: Carboplatin

• Registration Number: NCT04493619
• Lead Sponsor: Opna Bio LLC

Brief Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-23
• Study First Submitted QC: 2020-07-27
• Study First Posted: 2020-07-30
• Study Start: 2020-08-11
• Primary Completion: 2022-04-25
• Study Completion: 2022-04-25
• Results First Submitted: 2024-01-14
• Status Verified: 2024-10
• Results First Submitted QC: 2024-10-30
• Last Update Submitted: 2024-10-30
• Results First Posted: 2024-11-04
• Last Update Posted: 2024-11-04

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 37

Inclusion Criteria

1. Age ≥18 years at the time of signing informed consent

2. Histologically or cytologically confirmed diagnosis of 1 of the following, and must have measurable disease per RECIST v1.1:

   • Phase 2a (PLX2853 monotherapy): Any advanced gynecological malignancy (cervical, vaginal, vulvar, uterine, ovarian, fallopian tube, or primary peritoneal) with a known ARID1A mutation, that is intolerant to or refractory to all standard therapy known to confer clinical benefit.
   • Phase 1b and Phase 2a (PLX2853 + carboplatin combination):

   Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer).

3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1

4. Adequate organ function as demonstrated by laboratory values.

5. Women of child bearing potential (defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal) must have a negative serum pregnancy test within 7 days prior to taking the first dose of study drug and, if sexually active, must agree to use a highly effective method of contraception (a contraception method with a failure rate <1% per year) and 1 additional barrier method from the time of the negative pregnancy test to 90 days after the last dose of study drug. Women of non-child bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.

6. Except as specified above for organ function, all drug-related toxicity from previous cancer therapy must be resolved (to Grade ≤1 or baseline per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [NCI CTCAE v5.0]) prior to study treatment administration (Grade 2: alopecia, hot flashes, decreased libido, or neuropathy is allowed).

7. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements

Exclusion Criteria

1. Prior exposure to a bromodomain inhibitor

2. Ongoing systemic infection requiring treatment with antibiotic, antiviral, or antifungal treatment

3. Autoimmune hemolytic anemia or autoimmune thrombocytopenia

4. Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases

5. Red blood cell or platelet transfusion within 14 days of Screening blood draw

6. Known or suspected allergy to the investigational agent or any agent given in association with this study

7. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 μg (NIH-ODS 2020).

8. Use of strong inhibitors and inducers of CYP3A4 and 2C8

9. Clinically significant cardiac disease

10. Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption

11. Non-healing wound, ulcer, or bone fracture

12. Infection with HIV-1 or HIV-2. Exception: subjects with well-controlled HIV (e.g., CD4 >350/mm3 and undetectable viral load) are eligible.

13. Current active liver disease from any cause, including hepatitis A (hepatitis A virus immunoglobulin M positive), hepatitis B (hepatitis B virus [HBV] surface antigen positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid).

14. Active known second malignancy with the exception of any of the following:

    • Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
    • Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years
    • Any other cancer from which the subject has been disease-free for ≥3 years

15. Major surgery or significant traumatic injury within 28 days prior to Cycle 1 Day 1

16. Hospitalization for subacute bowel obstruction within 28 days prior to Cycle 1 Day 1

17. Receipt of anti-cancer therapy prior to Cycle 1 Day 1:

    • Chemotherapy, radiation therapy, or small molecule anti-cancer therapy for the treatment of cancer within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1
    • Immune therapy or other biologic therapy (e.g., monoclonal antibodies, antibody-drug conjugates) for the treatment of cancer within 21 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1 Subjects can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 28 days prior to treatment with study drug.

18. Subject is participating in any other therapeutic clinical study (observational or registry studies are allowed).

19. Subjects who are pregnant or breast-feeding

20. Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol or would interfere with the study endpoints or the subject's ability to participate.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Phase 1b PLX2853 (40 mg) + Carboplatin Combination Therapy	Carboplatin	Subjects with platinum-resistant EOC
Phase 2a PLX2853 (80 mg) + Carboplatin Combination Therapy	PLX2853	Subjects with platinum-resistant EOC
Phase 2a PLX2853 (80 mg) + Carboplatin Combination Therapy	Carboplatin	Subjects with platinum-resistant EOC
Phase 1b PLX2853 (80 mg) + Carboplatin Combination Therapy	PLX2853	Subjects with platinum-resistant EOC
Phase 1b PLX2853 (80 mg) + Carboplatin Combination Therapy	Carboplatin	Subjects with platinum-resistant EOC
Phase 2a PLX2853 Monotherapy (80 mg)	PLX2853	Subjects with ARID1A mutation-positive advanced gynecological malignancies
Phase 1b PLX2853 (40 mg) + Carboplatin Combination Therapy	PLX2853	Subjects with platinum-resistant EOC

Primary Outcome Measures

Name	Time	Method
Phase 2a (PLX2853 Monotherapy): Number of Participants With Overall Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	From 8 weeks of treatment for only PLX2853 (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.	Overall response rate as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Phase 1b (PLX2853 + Carboplatin Combination): Establish the Number of Participants Reaching MTD/RP2D for the Combination of PLX2853 and Carboplatin	From time of first dose of PLX2853 and carboplatin until 30 days of end of treatment an average of 6 months.	MTD is defined as the maximum tolerated dose, which is determined from dose-limiting toxicity. If DLTs are observed in 2 or more of 6 subjects (or ≥33% of the cohort) at a dose level, the dose at which this occurs will be considered intolerable and the MTD will have been exceeded. The MTD is the dose below the intolerable dose.; RP2D is the recommended Phase 2 dose, which was determined to be 80 mg
Phase 2a (PLX2853 + Carboplatin Combination): Number of Participants Reaching ORR as Measured by RECIST v1.1	From 8 weeks of treatment with PLX2853 and Carboplatin (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months.	Overall response rate as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Trial Locations

Locations (9)

University of Virginia Health Systems; 🇺🇸 Charlottesville, Virginia, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

University of Oklahoma - Stephenson Cancer Center; 🇺🇸 Oklahoma City, Oklahoma, United States

Tennessee Oncology / Sarah Cannon; 🇺🇸 Nashville, Tennessee, United States

The University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Virginia Cancer Specialists, PC; 🇺🇸 Fairfax, Virginia, United States

University of Washington / Seattle Cancer Care Alliance; 🇺🇸 Seattle, Washington, United States

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada